Clinical trial SHRINK
CELYAD SHRINK : An open-label, Phase I study to assess the safety and clinical activity of multiple doses of NKR-2, administered concurrently with the neoadjuvant Folfox treatment in patients with potentially resectable liver metastases from colorectal cancer
| Cancers | |
|---|---|
| Organ | Colon |
| Trial status | Trial closed |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1 |
| Academic trial | Non |
| Sponsor | Celyad |
| EudraCT Identifier | 2017-000616-41 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03310008 |
| Inclusion criteria | Biopsy mandatory neoadjuvant |
| Last update |